Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

422.00 +5.04 (+1.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions. 
Via Benzinga
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain
The company says there was variability among placebo responses at various sites. 
Via Investor's Business Daily
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Vertex Pharmaceuticals' drug reduced back pain significantly. 
Via Investor's Business Daily
2 Unstoppable Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
The Ultimate Biotech Stock to Buy With $500 Right Now
Via The Motley Fool
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments. 
Via Benzinga
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Got $500? 1 Biotech Stock to Buy and Hold Forever
Via The Motley Fool
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Via Benzinga
2 No-Brainer Stocks to Buy Before the End of 2024
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
It’s Been A Tough Month For Healthcare Stocks
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Regulators are reviewing what could become a multi-billion-dollar drug. 
Via The Motley Fool
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points
Meta just forged a new base. All five stocks are on the IBD Leaderboard list. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
< Previous 1 2 3 4 5 6 7 8 9
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.